SCHEMBL4816282

SCHEMBL4816282

CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CSCCCCCCCCCCCCCC

nearest known ligand 0.72

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.72
LMNA P02545 1/20 0.72
PRKCA P17252 4/20 0.62
PRKCE Q02156 2/20 0.62
PRKCQ Q04759 2/20 0.62
PRKCD Q05655 2/20 0.62
LPAR3 Q9UBY5 7/20 0.59
LPAR1 Q92633 4/20 0.59
ENPP2 Q13822 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
LPAR2 Q9HBW0 2/20 0.58
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813459 1.00 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL5936405 1.00 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL4814107 1.00 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL5936352 1.00 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL5944372 1.00 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL4812404 0.99 ALDH1A1 (0.70) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL5936406 0.94 ALDH1A1 (0.72) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL6026492 0.93 ALDH1A1 (0.59) ALDH1A1LMNAPRKCAPRKCEPRKCQ
SCHEMBL14178795 0.93 ALDH1A1 (0.59) ALDH1A1LMNAPRKCAPRKCEPRKCQ
Tritetradecylthioacetyl Glycerol SCHEMBL4815254 0.93 ALDH1A1 (0.59) ALDH1A1LMNAPRKCAPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154984-A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof GENFIT (FR) 2006-07-13 US claimed
EP-1596845-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF Genfit (FR) 2005-11-23 EP claimed
WO-2004073698-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF GENFIT (FR) 2004-09-02 WO claimed
US-7375135-B2 Fatty acid derivatives; preparation and uses thereof GENFIT (FR) 2008-05-20 US disclosed
US-7375135-B2 Fatty acid derivatives; preparation and uses thereof GENFIT (FR) 2008-05-20 US disclosed
EP-1673338-B1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF GENFIT (FR) 2007-09-19 EP disclosed
US-20060252827-A1 Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof GENFIT (FR) 2006-11-09 US disclosed
US-20060154984-A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof GENFIT (FR) 2006-07-13 US disclosed
EP-1673338-A1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF Genfit (FR) 2006-06-28 EP disclosed
EP-1596845-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF Genfit (FR) 2005-11-23 EP disclosed
EP-1587508-A1 THERAPEUTIC USE OF ACYLGLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEREOF Genfit (FR) 2005-10-26 EP disclosed
US-20040192908-A1 Fatty acid compounds, preparation and uses thereof GENFIT (FR) 2004-09-30 US disclosed
WO-2004073698-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF GENFIT (FR) 2004-09-02 WO disclosed
WO-2004069241-A1 THERAPEUTIC USE OF ACYLGLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEREOF GENFIT (FR) 2004-08-19 WO disclosed
WO-2003014073-A1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF GENFIT (FR) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252827-A1 Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof SGMS2, SGMS1, AGK ALDH1A1 3402/4885LMNA 4519/4885PRKCA 2280/4885
US-20040192908-A1 Fatty acid compounds, preparation and uses thereof FASN, FFAR1, PLIN5 ALDH1A1 1220/4885LMNA 239/4885PRKCA 574/4885
US-20060154984-A1 Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof AGPAT5, HAGH, AGPAT2 ALDH1A1 1482/4885LMNA 4213/4885PRKCA 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.